About Us

About Us

Greeting

Photograph of a laboratory at GlyTech, Inc.

GlyTech, Inc. is focused on the application of glycan production and chemical glycosylation technologies to the development of innovative and improved medicines such as biopharmaceuticals and oligonucleotide therapeutics.

Our platform glycan and glycosylation modification technologies can:

  • Improve the efficacy of a drug candidate
  • Ensure a uniform glycosylated structure
  • Reduce the cost of a glycosylated drug while increasing its quality

Biopharmaceuticals and oligonucleotide therapeutics have become indispensable in modern medicine as therapeutics for many chronic and acute diseases that require highly specific treatments. By aiding in the development and improvement of such medicines, we seek to improve the lives of individual patients and benefit society as a whole.

Our Approach

  • From single drug-glycan conjugates to libraries, we offer chemical glycosylation of target compounds with high purity human-type glycans to enhance their drug properties.
  • We work with research and development partners to screen for optimized glycosylation patterns and develop new drug candidates.
  • We supply the biopharmaceutical industry and life science community with highly pure, homogenous human-type N-glycans from research to production scale.

Company Overview

Profile

U.S. Office
Company Name GlyTech, Inc.
Date Established April 2nd, 2012
Locations Head Office
134 Chudoji Minamimachi KRP#1-109, Shimogyo-ku, Kyoto 600-8813, JAPAN
TEL : +81-75-315-9218
U.S. Office
3350 Scott Blvd. #29, Santa Clara, CA 95054, USA (GlyTech, Inc. c/o B-Bridge International)
TEL : +1-408-252-6200
Capital 571 million JPY
President & CEO Mr. Hiroaki Asai

History

History
April 2002 Otsuka Chemical Co. initiates a collaboration on N-glycan production with Prof Kajihara of Osaka University.
September 2006 Otsuka Chemical Co. receives a research grant from the Japan Science and Technology Agency (JST) for the development of mass-production technologies for human type N-glycans.
April 2007 Otsuka Chemical Co. begins test production of N-glycans at its pilot-plant in Tokushima.
April 2009 Otsuka Chemical Co. launches a glycotechnology laboratory.
April 2009 Otsuka Chemical Co. enters into a collaboration with American Peptide Company (now part of Bachem Holding AG) on commercial-scale glycopeptide manufacturing.
November 2011 Otsuka Chemical Co. enters into a collaboration with Bachem Holding AG for the development of glycoprotein synthesis technologies.
March 2012 First chemical synthesis of human interferon beta (hIFNβ) is reported in the Journal of the American Chemical Society.
April 2012 GlyTech, Inc. is founded as a subsidiary of Otsuka Chemical Co..
March 2013 GlyTech, Inc. becomes an independent company.
December 2013 GlyTech, Inc. raises 600 million JPY in capital from the The University of Tokyo Edge Capital Co. (UTEC), DBJ Capital Co., Mitsui Sumitomo Insurance Venture Capital and Mitsubishi UFJ Capital Co..
October 2015 GlyTech, Inc. signs capital and business alliance agreement with Nippon Shokubai Co..
April 2017 GlyTech, Inc. and Dr. Katsunori Tanaka of the RIKEN research institute establish a glycan targeting laboratory.
May 2018 GlyTech, Inc receives an investment of approximately 1 billion JPY from Nippon Shokubai Co., Fushimi Pharmaceutical Co., SBI Investment Co., Osaka University Venture Capital Co. and Miat S.p.A..